The ongoing AcceleRET Lung study is an international, open-label, randomized phase III trial (NCT04222972) designed to evaluate the efficacy and safety of pralsetinib compared to the standard of care for the first-line treatment of patients with advanced or metastatic RET-fusion-positive NSCLC [164]. The gene discussed is RET; the disease is non-small cell lung carcinoma.